AstraZeneca: announces $3.5bn investment in US
(CercleFinance.com) - AstraZeneca today announced a $3.
5bn investment in the US, aimed at expanding its research and production activities by the end of 2026.
The project includes $2bn to create more than a thousand highly skilled jobs, contributing to the growth of the US economy.
AstraZeneca plans to build a "state-of-the-art R&D center" in Massachusetts, a next-generation biotech manufacturing facility in Maryland, cell therapy production capacity on the West and East coasts, and specialty manufacturing in Texas.
By expanding our R&D and manufacturing activities, we aim to strengthen the development of cutting-edge therapies and support US leadership in healthcare innovation, AstraZeneca said.
These investments in the US mark the first steps towards AstraZeneca's ambition to generate $80bn in total sales by 2030, as announced last May.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
5bn investment in the US, aimed at expanding its research and production activities by the end of 2026.
The project includes $2bn to create more than a thousand highly skilled jobs, contributing to the growth of the US economy.
AstraZeneca plans to build a "state-of-the-art R&D center" in Massachusetts, a next-generation biotech manufacturing facility in Maryland, cell therapy production capacity on the West and East coasts, and specialty manufacturing in Texas.
By expanding our R&D and manufacturing activities, we aim to strengthen the development of cutting-edge therapies and support US leadership in healthcare innovation, AstraZeneca said.
These investments in the US mark the first steps towards AstraZeneca's ambition to generate $80bn in total sales by 2030, as announced last May.
Copyright (c) 2024 CercleFinance.com. All rights reserved.